Evidence map›Paper›PMID 30479631›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2018

The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey of Canadian physicians and laboratories.

Xavier Charest-Morin, Stephen Betschel, Rozita Borici-Mazi, Amin Kanani, Gina Lacuesta, Georges-Étienne Rivard, Eric Wagner, Susan Wasserman, Bill Yang, Christian Drouet

Abstract read
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Biomarkers in Hereditary Angioedema.Clinical reviews in allergy & immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xavier Charest-Morin1Department of Microbiology-Infectious Disease and Immunology, Laval University, Quebec, QC Canada.ORCID 0000-0002-1858-2577
Stephen Betschel2Division of Clinical Immunology and Allergy, St. Michael's Hospital, University of Toronto, Toronto, ON Canada.
Rozita Borici-Mazi3Division of Allergy and Immunology, Department of Medicine, Queen's University, Kingston, Canada.
Amin Kanani4Division of Allergy and Immunology, Department of Medicine, University of British Columbia, Vancouver, BC Canada.
Gina Lacuesta5Department of Medicine, Dalhousie University, Halifax, NS Canada.
Georges-Étienne Rivard6Hematology/Oncology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.
Eric Wagner7Immunology and Histocompatibility Laboratory, CHU de Quebec, Laval University, Quebec, QC Canada.
Susan Wasserman8Department of Medicine, McMaster University, Hamilton, ON Canada.
Bill Yang9University of Ottawa Medical School, Ottawa, ON Canada.
Christian Drouet10GREPI EA7408, University Grenoble Alpes, Grenoble, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is an autosomal dominant disease resulting in random and unpredictable attacks of swelling. The swelling in C1-INH-HAE is a result of impaired regulation of bradykinin production. The fact that the array of tests needed to diagnose HAE is not always available to the treating physicians is challenging for them and their patients.

methodsThe data for this article were extracted from two distinct surveys. The first survey was conducted among HAE treating physicians and aimed to determine the availability and utilization of the various assays performed to help the diagnosis of C1-INH-HAE. The second survey was conducted with the various laboratories across Canada that performs the assays used in the diagnosis of HAE. The aim of this survey was to determine the availability and profile of the various assays used in the diagnosis of C1-INH-HAE in Canada, thereby ultimately bringing a rational basis for the biological testing.

resultsC1-INH functional assay was widely available in Canada (93%), but was only offered by a small numbers of hospitals meaning that there could be longer delays in the analysis of these samples that may explain why the physicians expressed a lower level of confidence in this assay (59%). Antigenic C1-INH was available to the vast majority of the physicians treating C1-INH-HAE (93%) and was considered reliable by 96% of the respondents. Antigenic C4 was found available to all Canadian physicians and, although with limited specificity, was considered very reliable by all the participants. This study revealed that 81% of physicians were able to order the antigenic C1q and the confidence in this assay was moderate (70%). Concerning genetic testing, the survey revealed that most of the CHAEN members never had to or couldn't order this test.

conclusionThis study highlights the need for improved education and knowledge exchange, about biological assays available to Canadian physicians and their performance in proper diagnosis of C1-INH-HAE to improve confidence and access to relevant tests.

Indexed as

Biological diagnosticC1-inhibitorCanadaDiagnosisHereditary angioedema

Identifiers

PMID30479631
PMCPMC6249925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.